益盛药业(002566) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥229,097,736.43, representing a 14.31% increase compared to ¥200,410,031.97 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥27,765,054.54, up 29.24% from ¥21,483,641.33 in the previous year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥23,405,772.17, reflecting a 40.73% increase from ¥16,632,110.71 year-on-year[8]. - The basic earnings per share for Q1 2021 was ¥0.0839, a 29.28% increase from ¥0.0649 in the same period last year[8]. - The company achieved operating revenue of CNY 229,097,736.43, a year-on-year increase of 14.31%[18]. - Net profit attributable to shareholders reached CNY 27,765,054.54, up 29.24% compared to the same period last year[18]. - The total profit for the first quarter was CNY 39,024,730.06, an increase from CNY 29,813,960.90 year-over-year[42]. - The company reported a significant increase in operating profit, which was CNY 41,911,932.69, compared to CNY 31,513,381.89 in the previous year[42]. - Net profit for Q1 2021 increased to CNY 34,668,779.18, compared to CNY 26,187,829.40 in the same period last year[40]. - The total comprehensive income for the first quarter was CNY 33,186,719.33, compared to CNY 25,202,056.45 in the same period last year[42]. Cash Flow - The net cash flow from operating activities was ¥29,363,113.24, a decrease of 7.44% compared to ¥31,724,684.07 in the previous year[8]. - Cash flow from tax refunds increased by 63.62% to CNY 309,038.42, due to higher VAT refunds received[18]. - Total cash inflow from operating activities was ¥245,212,053.73, up from ¥236,143,130.92 in the previous year, reflecting a growth of 4.5%[49]. - Cash outflow from operating activities totaled ¥215,848,940.49, compared to ¥204,418,446.85 in the same period last year, indicating an increase of 5.5%[49]. - The company reported a net cash flow from investing activities of -¥13,880,051.32, worsening from -¥3,085,989.58 in Q1 2020[50]. - Cash inflow from financing activities was ¥50,000,000.00, down from ¥110,000,000.00 in the previous year, representing a decline of 54.5%[50]. - The net cash flow from financing activities was -¥12,241,385.43, compared to -¥2,899,569.82 in Q1 2020, indicating a significant increase in cash outflow[50]. - The ending balance of cash and cash equivalents was ¥290,238,191.42, an increase from ¥88,753,739.80 at the end of Q1 2020[50]. - The net increase in cash and cash equivalents for the period was ¥3,241,676.49, compared to an increase of ¥25,739,124.67 in Q1 2020[50]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,768,818,814.32, down 0.98% from ¥2,796,099,005.75 at the end of the previous year[8]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,023,482,992.17, an increase of 1.39% from ¥1,995,717,937.63 at the end of the previous year[8]. - Total assets as of March 31, 2021, amounted to CNY 2,809,491,036.17, compared to CNY 2,795,950,343.62 at the end of 2020[36]. - Total liabilities decreased to CNY 804,389,575.74 from CNY 853,772,344.48 at the end of 2020[37]. - The company's equity increased to CNY 2,005,101,460.43 from CNY 1,942,177,999.14 at the end of 2020[37]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,899[12]. - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[12]. Expenses - Management expenses rose by 24.15% to CNY 24,930,308.88, attributed to increased employee insurance and salary costs[18]. - Financial expenses decreased by 55.55% to CNY 1,314,678.47, mainly due to increased interest from agreement deposits[18]. - Research and development expenses for Q1 2021 were CNY 4,823,806.99, compared to CNY 4,295,439.68 in the previous period[40]. - The company incurred financial expenses of CNY 2,503,292.90, down from CNY 4,483,604.94 in the previous year[44]. - Research and development expenses for the first quarter were CNY 3,643,031.48, compared to CNY 3,472,786.86 in the previous year[44].